quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:30:00·14d
PRRelease
Kura Oncology Inc. logo

Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026

KURA· Kura Oncology Inc.
Health Care
Original source

Companies

  • KURA
    Kura Oncology Inc.
    Health Care

Recent analyst ratings

  • Apr 14UpdateLake Street$23.00
  • Sep 4UpdateGuggenheim-
  • Feb 6UpdateBTIG Research-
  • Oct 24UpdateUBS$27.00
  • Oct 14UpdateStifel$19.00
  • Dec 22UpdateMizuho$26.00

Related

  • PR6d
    Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib
  • ANALYST9d
    Lake Street initiated coverage on Kura Oncology with a new price target
  • SEC13d
    SEC Form DEFA14A filed by Kura Oncology Inc.
  • SEC13d
    SEC Form DEF 14A filed by Kura Oncology Inc.
  • PR20d
    Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Kura Oncology Inc.
  • INSIDER29d
    SEC Form 4 filed by Wilson Troy Edward
  • INSIDER34d
    SEC Form 4 filed by Malley Thomas
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022